UNderstanding the RAdiobiology of therapeutic medical radioNUclides (UNRANU)
Cancer is a leading cause of death worldwide. Most patients with metastasised disease can no longer be cured. So-called radionuclide therapy can substantially improve their survival. Patients undergoing this therapy are administered substances containing radioactive atoms – the radionuclide.
These substances will specifically move to and bind to the tumour, irradiating it from the inside. The UNRANU programme develops new production routes for these radionuclides, finds the best match between radionuclide and tumour type, determines the optimal treatment dose, and investigates how treatment effectiveness is influenced by the immune system.
Programme leader
Dr Frank Nijsen (Radboudumc)
Participating knowledge institutes
Erasmus MC, Oncode, RIVM National Institute for Public Health and the Environment, Radboudumc, TU Delft
Companies
AlfaRIM, HUB Organoids, MILabs, NRG, PALLAS, Quirem Medical, Terumo, RTM, Siemens Healthineers, TerThera, URENCO, Von Gahlen, VSL
Other social partners
Meander Medisch Centrum, Nederlandse Leverpatiënten Vereniging, Nederlandse Vereniging van Nucleaire Geneeskunde, Prostaatkanker Stichting, Reiner de Graaf Ziekenhuis, Science Education Hub Radboud University, Stichting darmkanker
